{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:11:16Z","timestamp":1791925876680,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Knee osteoarthritis is a degenerative joint disease, with no fundamental cure beyond pain relief and anti-inflammation. This phase I, multicenter, open-label, dose-escalation trial evaluated the safety, tolerability, and preliminary efficacy of OSCA, an intra-articular injection co-formulation of osiramestrocel (allogeneic mesenchymal stromal cells) and cartilage acellular matrix, in patients with Kellgren\u2013Lawrence (K&amp;L) grade 2 or 3 knee osteoarthritis. Twelve patients received a single intra-articular injection of OSCA at low (2.5 \u00d7 10\n                    <jats:sup>7<\/jats:sup>\n                    cells,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093), mid (5.0 \u00d7 10\n                    <jats:sup>7<\/jats:sup>\n                    cells,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093), or high (1.0 \u00d7 10\n                    <jats:sup>8<\/jats:sup>\n                    cells,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20096) doses; cell concentration was 3.3 \u00d7 10\n                    <jats:sup>7<\/jats:sup>\n                    cells\/ml for all cohorts, and cartilage acellular matrix was 60\u2009mg (40\u2009mg\/ml). The primary end point was safety, assessed by dose-limiting toxicities and TEAEs. Secondary end points included Visual Analog Scale (VAS), International Knee Documentation Committee (IKDC), Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART), Whole-Organ Magnetic Resonance Imaging Score (WORMS), and K&amp;L grading over 24 weeks. OSCA was well tolerated, with no dose-limiting toxicities and mild-to-moderate TEAEs in 25.0% (3\/12) of patients. At 24 weeks, mid-dose and high-dose groups showed numerically greater improvement in pain and function than the low-dose group (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05), with up to 91.3% reduction in VAS (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.002) and 102.7% IKDC (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005). MRI outcomes showed efficacy signals: MOCART total scores improved in 70% of patients, WORMS cartilage integrity improved in 50%, and K&amp;L grades remained stable in 80%. Overall, these findings support the feasibility and tolerability of a single OSCA injection, with exploratory efficacy in both clinical and MRI outcomes.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01728-w","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:17Z","timestamp":1777593677000},"page":"1510-1521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["First-in-human and multicenter phase I study of OSCA therapy for knee osteoarthritis"],"prefix":"10.1038","volume":"58","author":[{"given":"Dae Keun","family":"Suh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohan","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee-Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JongCheon","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-1286","authenticated-orcid":false,"given":"Ali","family":"Mobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-741X","authenticated-orcid":false,"given":"Kyung-Sun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"1728_CR1","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/S0140-6736(18)31064-X","volume":"391","author":"R Barnett","year":"2018","unstructured":"Barnett, R. Osteoarthritis. Lancet 391, 1985 (2018).","journal-title":"Lancet"},{"key":"1728_CR2","doi-asserted-by":"publisher","first-page":"1759720x2311698","DOI":"10.1177\/1759720X231169839","volume":"15","author":"S Li","year":"2023","unstructured":"Li, S., Cao, P., Chen, T. & Ding, C. Latest insights in disease-modifying osteoarthritis drugs development. Ther Adv Musculoskelet Dis. 15, 1759720x231169839 (2023).","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1728_CR3","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/S0140-6736(19)30417-9","volume":"393","author":"DJ Hunter","year":"2019","unstructured":"Hunter, D. J. & Bierma-Zeinstra, S. Osteoarthritis. Lancet 393, 1745\u20131759 (2019).","journal-title":"Lancet"},{"key":"1728_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/bmb\/lds038","volume":"105","author":"A Litwic","year":"2013","unstructured":"Litwic, A., Edwards, M. H., Dennison, E. M. & Cooper, C. Epidemiology and burden of osteoarthritis. Br. Med. Bull. 105, 185\u2013199 (2013).","journal-title":"Br. Med. Bull."},{"key":"1728_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMcp1903768","volume":"384","author":"L Sharma","year":"2021","unstructured":"Sharma, L. Osteoarthritis of the knee. N. Engl. J. Med. 384, 51\u201359 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1728_CR6","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1177\/03635465211029659","volume":"50","author":"H Singh","year":"2022","unstructured":"Singh, H. et al. Relative efficacy of intra-articular injections in the treatment of knee osteoarthritis: a systematic review and network meta-analysis. Am. J. Sports Med. 50, 3140\u20133148 (2022).","journal-title":"Am. J. Sports Med."},{"key":"1728_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru, R. R. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthr. Cartil. 27, 1578\u20131589 (2019).","journal-title":"Osteoarthr. Cartil."},{"key":"1728_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jcb.22701","volume":"111","author":"D Chanda","year":"2010","unstructured":"Chanda, D., Kumar, S. & Ponnazhagan, S. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J. Cell. Biochem. 111, 249\u2013257 (2010).","journal-title":"J. Cell. Biochem."},{"key":"1728_CR9","first-page":"6275","volume":"11","author":"R Zhang","year":"2019","unstructured":"Zhang, R., Ma, J., Han, J., Zhang, W. & Ma, J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. Am. J. Transl. Res. 11, 6275\u20136289 (2019).","journal-title":"Am. J. Transl. Res."},{"key":"1728_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.5966\/sctm.2016-0157","volume":"6","author":"YB Park","year":"2017","unstructured":"Park, Y. B., Ha, C. W., Lee, C. H., Yoon, Y. C. & Park, Y. G. Cartilage regeneration in osteoarthritic patients by a composite of allogeneic umbilical cord blood-derived mesenchymal stem cells and hyaluronate hydrogel: results from a clinical trial for safety and proof-of-concept with 7 years of extended follow-up. Stem Cells Transl. Med. 6, 613\u2013621 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"1728_CR11","doi-asserted-by":"crossref","unstructured":"Lee, D. H. et al. Cartilage regeneration using human umbilical cord blood derived mesenchymal stem cells: asystemati c review and meta-analysis. Medicina (Kaunas) 58,1801 (2022).","DOI":"10.3390\/medicina58121801"},{"key":"1728_CR12","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.arthro.2021.02.022","volume":"37","author":"NH Lee","year":"2021","unstructured":"Lee, N. H. et al. Allogenic human umbilical cord blood-derived mesenchymal stem cells are more effective than bone marrow aspiration concentrate for cartilage regeneration after high tibial osteotomy in medial unicompartmental osteoarthritis of knee. Arthroscopy 37, 2521\u20132530 (2021).","journal-title":"Arthroscopy"},{"key":"1728_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/sctm.18-0053","volume":"8","author":"J Matas","year":"2019","unstructured":"Matas, J. et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I\/II trial. Stem Cells Transl. Med. 8, 215\u2013224 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"1728_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/03635465211053893","volume":"51","author":"KI Kim","year":"2023","unstructured":"Kim, K. I., Kim, M. S. & Kim, J. H. Intra-articular injection of autologous adipose-derived stem cells or stromal vascular fractions: are they effective for patients with knee osteoarthritis? A systematic review with meta-analysis of randomized controlled trials. Am. J. Sports Med. 51, 837\u2013848 (2023).","journal-title":"Am. J. Sports Med."},{"key":"1728_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.reth.2020.04.003","volume":"14","author":"J Higuchi","year":"2020","unstructured":"Higuchi, J. et al. Associations of clinical outcomes and MRI findings in intra-articular administration of autologous adipose-derived stem cells for knee osteoarthritis. Regen. Ther. 14, 332\u2013340 (2020).","journal-title":"Regen. Ther."},{"key":"1728_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4252\/wjsc.v2.i2.34","volume":"2","author":"JY Kim","year":"2010","unstructured":"Kim, J. Y., Jeon, H. B., Yang, Y. S., Oh, W. & Chang, J. W. Application of human umbilical cord blood-derived mesenchymal stem cells in disease models. World J. Stem Cells 2, 34\u201338 (2010).","journal-title":"World J. Stem Cells"},{"key":"1728_CR17","doi-asserted-by":"publisher","first-page":"6380141","DOI":"10.1155\/2021\/6380141","volume":"2021","author":"G Yang","year":"2021","unstructured":"Yang, G. et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells improves cartilage repair in a rabbit model. Biomed. Res. Int. 2021, 6380141 (2021).","journal-title":"Biomed. Res. Int."},{"key":"1728_CR18","doi-asserted-by":"crossref","unstructured":"Molnar, V. et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int. J. Mol. Sci. 22, 9208 (2021).","DOI":"10.3390\/ijms22179208"},{"key":"1728_CR19","first-page":"4993","volume":"20","author":"J Yang","year":"2019","unstructured":"Yang, J. et al. IL\u20111\u03b2 increases the expression of inflammatory factors in synovial fluid\u2011derived fibroblast\u2011like synoviocytes via activation of the NF\u2011\u03baB\u2011mediated ERK\u2011STAT1 signaling pathway. Mol. Med. Rep. 20, 4993\u20135001 (2019).","journal-title":"Mol. Med. Rep."},{"key":"1728_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00223-020-00701-7","volume":"109","author":"VB Kraus","year":"2021","unstructured":"Kraus, V. B. & Karsdal, M. A. Osteoarthritis: current molecular biomarkers and the way forward. Calcif. Tissue Int. 109, 329\u2013338 (2021).","journal-title":"Calcif. Tissue Int."},{"key":"1728_CR21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.joca.2018.03.007","volume":"26","author":"ZH Deng","year":"2018","unstructured":"Deng, Z. H., Li, Y. S., Gao, X., Lei, G. H. & Huard, J. Bone morphogenetic proteins for articular cartilage regeneration. Osteoarthr. Cartil. 26, 1153\u20131161 (2018).","journal-title":"Osteoarthr. Cartil."},{"key":"1728_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s13770-021-00407-3","volume":"19","author":"M Kim","year":"2022","unstructured":"Kim, M. et al. Combined mesenchymal stem cells and cartilage acellular matrix injection therapy for osteoarthritis in goats. Tissue Eng. Regen. Med. 19, 177\u2013187 (2022).","journal-title":"Tissue Eng. Regen. Med."},{"key":"1728_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s12015-020-09958-9","volume":"16","author":"HJ Jeon","year":"2020","unstructured":"Jeon, H. J. et al. Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells combined with cartilage acellular matrix mediated via bone morphogenic protein 6 in a rabbit model of articular cruciate ligament transection. Stem Cell Rev Rep. 16, 596\u2013611 (2020).","journal-title":"Stem Cell Rev Rep"},{"key":"1728_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","volume":"7","author":"E Basch","year":"2006","unstructured":"Basch, E. et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7, 903\u2013909 (2006).","journal-title":"Lancet Oncol"},{"key":"1728_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.5792\/ksrr.2013.25.3.106","volume":"25","author":"JG Kim","year":"2013","unstructured":"Kim, J. G. et al. Translation and validation of the Korean version of the International Knee Documentation Committee subjective knee form. Knee Surg. Relat. Res. 25, 106\u2013111 (2013).","journal-title":"Knee Surg. Relat. Res."},{"key":"1728_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2519\/jospt.1998.28.2.88","volume":"28","author":"EM Roos","year":"1998","unstructured":"Roos, E. M., Roos, H. P., Lohmander, L. S., Ekdahl, C. & Beynnon, B. D. Knee Injury and Osteoarthritis Outcome Score (KOOS) \u2014 development of a self-administered outcome measure. J. Orthop. Sports Phys. Ther. 28, 88\u201396 (1998).","journal-title":"J. Orthop. Sports Phys. Ther."},{"key":"1728_CR27","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy, N., Buchanan, W. W., Goldsmith, C. H., Campbell, J. & Stitt, L. W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15, 1833\u20131840 (1988).","journal-title":"J. Rheumatol."},{"key":"1728_CR28","doi-asserted-by":"crossref","unstructured":"Hawker, G. A., Mian, S., Kendzerska, T. & French, M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res. (Hoboken) 63, S240\u2013S252 (2011).","DOI":"10.1002\/acr.20543"},{"key":"1728_CR29","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","volume":"12","author":"T Pham","year":"2004","unstructured":"Pham, T. et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr. Cartil. 12, 389\u2013399 (2004).","journal-title":"Osteoarthr. Cartil."},{"key":"1728_CR30","doi-asserted-by":"publisher","first-page":"571s","DOI":"10.1177\/1947603519865308","volume":"13","author":"MM Schreiner","year":"2021","unstructured":"Schreiner, M. M. et al. The MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) 2.0 Knee Score and Atlas. Cartilage 13, 571s\u2013587s (2021).","journal-title":"Cartilage"},{"key":"1728_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.joca.2003.11.003","volume":"12","author":"CG Peterfy","year":"2004","unstructured":"Peterfy, C. G. et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthr Cartil. 12, 177\u2013190 (2004).","journal-title":"Osteoarthr Cartil"},{"key":"1728_CR32","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2019.14735","volume":"322","author":"MC Hochberg","year":"2019","unstructured":"Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 322, 1360\u20131370 (2019).","journal-title":"JAMA"},{"key":"1728_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00402-019-03140-8","volume":"139","author":"SH Kim","year":"2019","unstructured":"Kim, S. H. et al. Intra-articular injection of mesenchymal stem cells for clinical outcomes and cartilage repair in osteoarthritis of the knee: a meta-analysis of randomized controlled trials. Arch. Orthop. Trauma Surg. 139, 971\u2013980 (2019).","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"1728_CR34","doi-asserted-by":"publisher","first-page":"232596712097305","DOI":"10.1177\/2325967120973052","volume":"9","author":"HC Lim","year":"2021","unstructured":"Lim, H. C. et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell implantation versus microfracture for large, full-thickness cartilage defects in older patients: a multicenter randomized clinical trial and extended 5-year clinical follow-up. Orthop. J. Sports Med. 9, 2325967120973052 (2021).","journal-title":"Orthop. J. Sports Med."},{"key":"1728_CR35","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrrheum.2013.109","volume":"9","author":"F Barry","year":"2013","unstructured":"Barry, F. & Murphy, M. Mesenchymal stem cells in joint disease and repair. Nat. Rev. Rheumatol. 9, 584\u2013594 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1728_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4252\/wjsc.v11.i4.222","volume":"11","author":"AT Wang","year":"2019","unstructured":"Wang, A. T., Feng, Y., Jia, H. H., Zhao, M. & Yu, H. Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: a concise review. World J. Stem Cells 11, 222\u2013235 (2019).","journal-title":"World J. Stem Cells"},{"key":"1728_CR37","doi-asserted-by":"publisher","first-page":"116458","DOI":"10.1016\/j.biopha.2024.116458","volume":"173","author":"R Tian","year":"2024","unstructured":"Tian, R. et al. Revolutionizing osteoarthritis treatment: how mesenchymal stem cells hold the key. Biomed. Pharmacother. 173, 116458 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1728_CR38","doi-asserted-by":"crossref","unstructured":"Yoo, K. H. et al. Transforming growth factor\u2011\u03b2 family and stem cell\u2011derived exosome therapeutic treatment inosteoart hritis (Review). Int. J. Mol. Med. 49, 62 (2022).","DOI":"10.3892\/ijmm.2022.5118"},{"key":"1728_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.joca.2007.02.005","volume":"15","author":"EN Blaney Davidson","year":"2007","unstructured":"Blaney Davidson, E. N., van der Kraan, P. M. & van den Berg, W. B. TGF-beta and osteoarthritis. Osteoarthr. Cartil. 15, 597\u2013604 (2007).","journal-title":"Osteoarthr. Cartil."},{"key":"1728_CR40","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1002\/art.23034","volume":"56","author":"EN Blaney Davidson","year":"2007","unstructured":"Blaney Davidson, E. N. et al. Resemblance of osteophytes in experimental osteoarthritis to transforming growth factor beta-induced osteophytes: limited role of bone morphogenetic protein in early osteoarthritic osteophyte formation. Arthritis Rheum 56, 4065\u20134073 (2007).","journal-title":"Arthritis Rheum"},{"key":"1728_CR41","first-page":"279","volume":"71","author":"HM van Beuningen","year":"1994","unstructured":"van Beuningen, H. M., van der Kraan, P. M., Arntz, O. J. & van den Berg, W. B. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab. Invest. 71, 279\u2013290 (1994).","journal-title":"Lab. Invest."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01728-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01728-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:23:52Z","timestamp":1780539832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01728-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1728"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01728-w","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.-J.K., Y.B., S.H.L., M.K., and J.C.N. are employees of Kangstem Biotech Co., Ltd, and K.-S.K. is the Founder of Kangstem Biotech Co., Ltd. This commercial affiliation did not have any role in the data collection and analysis. All other authors declare no conflicts of interest in the authorship or publication of this contribution.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}